Literature DB >> 26975810

A global view of pulmonary hypertension.

Marius M Hoeper1, Marc Humbert2, Rogerio Souza3, Majdy Idrees4, Steven M Kawut5, Karen Sliwa-Hahnle6, Zhi-Cheng Jing7, J Simon R Gibbs8.   

Abstract

Pulmonary hypertension is a substantial global health issue. All age groups are affected with rapidly growing importance in elderly people, particularly in countries with ageing populations. Present estimates suggest a pulmonary hypertension prevalence of about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. In almost all parts of the world, left-sided heart and lung diseases have become the most frequent causes of pulmonary hypertension. About 80% of affected patients live in developing countries, where pulmonary hypertension is frequently associated with congenital heart disease and various infectious disorders, including schistosomiasis, HIV, and rheumatic heart disease. These forms of pulmonary hypertension occur predominantly in those younger than 65 years. Independently of the underlying disease, the development of pulmonary hypertension is associated with clinical deterioration and a substantially increased mortality risk. Global research efforts are needed to establish preventive strategies and treatments for the various types of pulmonary hypertension.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26975810     DOI: 10.1016/S2213-2600(15)00543-3

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  135 in total

1.  Multiscale structure-function relationships in right ventricular failure due to pressure overload.

Authors:  Tik-Chee Cheng; Jennifer L Philip; Diana M Tabima; Timothy A Hacker; Naomi C Chesler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-08       Impact factor: 4.733

Review 2.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

Review 3.  Sm-p80-Based Schistosomiasis Vaccine: Preparation for Human Clinical Trials.

Authors:  Afzal A Siddiqui; Sabrina Z Siddiqui
Journal:  Trends Parasitol       Date:  2016-11-16

Review 4.  HIV Infection and Risk of Cardiovascular Diseases Beyond Coronary Artery Disease.

Authors:  Revery P Barnes; John Charles A Lacson; Hossein Bahrami
Journal:  Curr Atheroscler Rep       Date:  2017-05       Impact factor: 5.113

Review 5.  [Arrhythmias in patients with pulmonary hypertension and chronic lung disease].

Authors:  Dirk Bandorski; Reinhard Höltgen; Ardeschir Ghofrani; Viktoria Johnson; Jörn Schmitt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2019-08-22

Review 6.  Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa.

Authors:  Anastase Dzudie; Bonaventure Suiru Dzekem; Dike B Ojji; Andre Pascal Kengne; Ana Olga Mocumbi; Karen Sliwa; Friedrich Thienemann
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

Review 7.  Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

Authors:  Andrea L Frump; Sébastien Bonnet; Vinicio A de Jesus Perez; Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-02       Impact factor: 5.464

8.  Dysregulation of miR-135a-5p promotes the development of rat pulmonary arterial hypertension in vivo and in vitro.

Authors:  Hong-Mei Liu; Yi Jia; Ying-Xian Zhang; Jun Yan; Ning Liao; Xiao-Hui Li; Yuan Tang
Journal:  Acta Pharmacol Sin       Date:  2018-07-23       Impact factor: 6.150

Review 9.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

10.  Effects of 17β-estradiol and 2-methoxyestradiol on the oxidative stress-hypoxia inducible factor-1 pathway in hypoxic pulmonary hypertensive rats.

Authors:  Li Wang; Quan Zheng; Yadong Yuan; Yanpeng Li; Xiaowei Gong
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.